tirzepatide and afib ESC 2025: study supports use of semaglutide, in cardiometabolic HFpEF patients HRS 2025: Exploring the Effects

Semaglutide requires gradual dose escalation over 45 months to minimize gastrointestinal side effects like nausea, which affects approximately 44% of patients

However, these products (as well as others with demonstrated lipid-lowering properties) may provide a good solution for: (1) statin-ineligible patients receiving early pharmacotherapy of dyslipidaemia, (2) patients declining statin therapy, (3) statin-intolerant patients, and (4) all those who (both in primary and secondary prevention), despite available treatment, still fail to achieve the treatment goal

More concerning, Professor Arne Astrup, the vice-president of the Novo Nordisk Foundations obesity program, serves as a paid adviser to Ferrero and has also collaborated with McDonalds, McCain Foods and Nestl, raising major conflict of interest concerns

HPLC, High-performance liquid chromatography